Evaluating blood flow in rare eye diseases using advanced imaging

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess blood flow in the retina and choroid using Doppler optical coherence tomography (OCT) and OCT angiography. By comparing blood flow in patients with rare retinal and choroidal diseases to healthy eyes, the study seeks to identify correlations between altered blood flow and areas of damage detected through conventional testing. The use of non-invasive OCT technology allows for real-time imaging and quantitative measurements, potentially offering a safer alternative to traditional fluorescein angiography. The findings could enhance understanding of disease etiology and inform treatment responses.

Why it matters

Who can join: the full rules

Subject-Level Criteria:

Inclusion a. Diagnosis of retinal or choroidal disease

Exclusion

1. Inability to give informed consent.
2. Inability to complete study tests within a 30 day period
3. Significant renal disease, defined as a history of chornic renal failure requiring dialysis or kidney transplant.
4. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g. unstable medical status including blood pressure, cardiovascular disease, and glycemic control).
5. Blood pressure \> 180/110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, subject can become eligible.
6. Women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months due to unknown safety of fluorescein angiography.

Study-Eye Criteria:

Inclusion

a. Diagnosis of retinal or choroidal disease

Exclusion

1. Inability to maintain stable fixation for OCT imaging.
2. An ocular condition is present that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study (i.e. cataract)
3. Substantial cataract that, in the opinion of the investigator, is likely to decrease visual acuity by 3 lines or more (i.e. cataract would be reducing acuity to 20/40 or worse if the eye was otherwise normal).
4. Media opacity or otherwise that would prevent either fixation or ability to obtain adequate images as determined by the examiner.

Where it's running

• Casey Eye Institute, Oregon Health & Science University
  Portland, Oregon, United States Recruiting

Study contacts

• Principal investigator: Thomas Hwang, MD — Oregon Health & Science Univeristy
• Study coordinator: Kevin Lathrop
• Email: lathropk@ohsu.edu
• Phone: 503-494-8024

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized high‑dose (8 mg) aflibercept treatment for treatment‑naive polypoidal choroidal vasculopathy

  This study will test whether a personalized high‑dose (8 mg) aflibercept schedule, using flexible loading and 8–24 week treatment intervals, helps people with newly diagnosed PCV in the macula.

  Recruiting Phase 3 Yeungnam University College of Medicine · Daegu · NCT07389980

• Faricimab for Caucasian patients with polypoidal choroidal vasculopathy (PCV)

  This trial will test whether intravitreal faricimab injections can improve vision and lengthen time between treatments for Caucasian adults aged 50 and older with symptomatic macular PCV.

  Recruiting at 16 sites Phase 4 Association for Innovation and Biomedical Research on Light and Image · Milan and 30 other locations · NCT06709339

• Investigating the link between gut bacteria and central serous chorioretinopathy

  This study is testing if the bacteria in our gut are connected to central serous chorioretinopathy and whether taking Bifidobacterium supplements can help improve vision and gut health in people with this eye condition.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hanzhou, Zhejiang · NCT06527326

• Evaluating Micropulse Laser Treatment for Central Serous Chorioretinopathy

  This study is testing if a special laser treatment can help people with central serous chorioretinopathy who haven't improved with other medications.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, R · NCT06346405

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.